Korean J Med.
2012 Aug;83(2):287-290.
A Case of Anti-Cyclic Citrullinated Peptide Antibody-Positive Rheumatoid Arthritis Following Peginterferon Alpha-2A and Ribavirin Therapy for Chronic Hepatitis C
- Affiliations
-
- 1Department of Internal Medicine, Busan St. Mary's Medical Center, Busan, Korea. gesundheit@paran.com
- 2Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Abstract
- Combination therapy with pegylated interferon (IFN) and ribavirin is the mainstay of treatment for chronic hepatitis C. An important side effect of IFN is the induction of an autoimmune disease such as autoimmune thyroid disease or, rarely, rheumatoid arthritis. However, the introduction of pegylated formulations of IFN can minimize the risk of autoimmune induction by reducing immunogenicity. Detection of anti-cyclic citrullinated peptide (anti-CCP) antibodies can help distinguish rheumatoid arthritis from hepatitis C-related arthritis. Here, we report the first Korean case of a 48-year-old female who developed anti-CCP antibody-positive rheumatoid arthritis following peginterferon alpha-2a therapy for hepatitis C.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patients
- Association of Anti-cyclic Citrullinated Peptide (CCP) Antibodies and Functional Status in Rheumatoid Arthritis
- Peginterferon-alpha and Ribavirin Combination Therapy in Chronic Hepatitis C
- Diagnostic Role of the Anti-Cyclic Citrullinated Peptide Antibodies in Rheumatoid Arthritis
- Permanent sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment
